Logo image of BIOL

BIOLASE INC (BIOL) Stock News

NASDAQ:BIOL - Nasdaq - US0909117022 - Common Stock - Currency: USD

0.129  -0.02 (-13.19%)

After market: 0.109 -0.02 (-15.5%)

BIOL Latest News, Press Relases and Analysis

News Image
10 months ago - BusinessInsider

BIOL Stock Earnings: Biolase Misses EPS, Misses Revenue for Q2 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biolase (NASDAQ:BIOL) just reported results for the second quarter of 2024.Biol...

News Image
10 months ago - InvestorPlace

BIOL Stock Earnings: Biolase Misses EPS, Misses Revenue for Q2 2024

BIOL stock results show that Biolase missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024.

News Image
a year ago - BusinessInsider

BIOL Stock Earnings: Biolase Misses EPS, Beats Revenue for Q1 2024

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biolase (NASDAQ:BIOL) just reported results for the first quarter of 2024.Biola...

News Image
a year ago - BusinessInsider

BIOL Stock Earnings: Biolase Beats EPS, Misses Revenue for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biolase (NASDAQ:BIOL) just reported results for the fourth quarter of 2023.Biol...

News Image
a year ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to start the day with a breakdown of the biggest pre-market stock movers worth keeping an eye on for Tuesday morning!

Mentions: NLSP ASNS MLGO SILK ...

News Image
a year ago - InvestorPlace

BIOL Stock Earnings: Biolase Misses EPS, Beats Revenue for Q1 2024

BIOL stock results show that Biolase missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.

News Image
a year ago - InvestorPlace

BIOL Stock Earnings: Biolase Beats EPS, Misses Revenue for Q4 2023

BIOL stock results show that Biolase beat analyst estimates for earnings per share but missed on revenue for the fourth quarter of 2023.

News Image
a year ago - Seeking Alpha

Biolase granted extension by NASDAQ to regain compliance (NASDAQ:BIOL)

BIOLASE has been granted an extension by Nasdaq to regain compliance with Listing Rule 5550(b), which requires certain financial criteria to be met.